Karen Reckamp, MD

Karen L. Reckamp, MD, discusses the feasibility of future pragmatic clinical trials for patients with lung cancer.

Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.

Karen Reckamp, MD, compares capmatinib and tepotinib, 2 drugs that are approved for the treatment of MET exon 14–mutated non–small cell lung cancer.

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Dr. Karen Reckamp from the City of Hope Cancer Center Discusses the Use of Hsp90 Inhibitors

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

Dr. Karen Reckamp from City of Hope Cancer center Discusses Heat Shock Proteins in Lung Cancer